抑制SGLT2,循环代谢物和心房动:孟德尔的随机化研究
Jiang Li1, Yuefeng Yu1, Ying Sun1
1Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cardiovascular diabetology
|October 18, 2023
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂可能会降低心房动 (AF) 的风险,可能是通过对脂蛋白颗粒的影响. 需要进一步的研究来澄清这些代谢机制.
科学领域:
- 心脏病学 心脏病学
- 代谢医学是一种代谢医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂显示出降低心房动 (AF) 风险的潜力.
- 这种关联的确切代谢机制尚不清楚.
- SGLT2 抑制剂可能会影响除葡萄糖调节之外的循环代谢物,影响AF风险.
研究的目的:
- 研究循环代谢物在调解SGLT2抑制对AF的影响中的作用.
- 使用门德尔的随机化 (MR) 来探索这些关联.
主要方法:
- 进行了一项由两个样本组成的两步MR研究.
- 与SLC5A2基因表达和HbA1c相关的遗传变异被用作SGLT2抑制的工具.
- 分析了基因预测SGLT2抑制,循环代谢物和AF之间的关联.
主要成果:
- 基因预测的SGLT2抑制与AF风险降低有关 (OR=0.51,P=0.039).
- 两种代谢物,总脂蛋白颗粒和高密度脂蛋白颗粒被确定为潜在的介质.
- 脂蛋白颗粒度介于SGLT2抑制对AF的影响的8.03%和HDL颗粒介于7.59%
结论:
- 抑制SGLT2与较低的AF风险有关.
- 循环中的脂蛋白颗粒度,特别是高密度脂蛋白,可能会介导这种保护作用.
- 需要进一步的研究来阐明血脂在SGLT2抑制-AF关系中的作用.
相关概念视频
Genome-wide Association Studies-GWAS
13.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Antihypertensive Drugs: Angiotensin II Receptor Blockers
752
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
752


